Enhancing Radiotherapy Outcomes for Oesophageal Cancer (Deadline extended)
Dr M Hawkins, Prof F Van den Heuvel
30 April 2019
Inhibition of ATR (a DNA damage checkpoint kinase) is currently being evaluated with radiotherapy and chemoradiation in patients with oesophageal cancer in the Cancer Research UK/MRC funded CHARIOT clinical study, whilst dose escalation is being evaluated in the SCOPE 2 clinical study.
Efficient and effective adaptive radiotherapy
Dr N Hardcastle, Dr A Yeo
Applications accepted all year round
Approximately 40% of cancer patients benefit from radiotherapy. Radiotherapy involves highly targeted radiation beams directed at the tumour, whilst avoiding surrounding normal tissues.